MetaVia Inc. Share Price
NASDAQ: MTVA | Micro CapMetaVia Inc. Stock Performance
Open $1.48 | Prev. Close $1.47 | Circuit Range N/A |
Day Range $1.48 - $1.53 | Year Range $0.57 - $12.68 | Volume 1,615 |
Average Traded $1.50 |
MetaVia Inc. Share Price Today
As of 10 August 2026, MetaVia Inc.'s share price is $1.49. The stock opened at $1.48, compared to its previous close of $1.47. During today's trading session, MetaVia Inc.'s share price traded between $1.48 and $1.53, with an average price of $1.50. Over the past 52 weeks, the stock has recorded a high of $12.68 and a low of $0.57. In terms of performance, MetaVia Inc.'s share price has declined by 1.32% over the last six months and is up 129.94% on a year-on-year basis.
MetaVia Inc. Share Price Chart
MetaVia Inc. Stock Fundamentals & Key Indicators
Market Cap $2.63M | PE Ratio (TTM) -0.20 | Dividend Yield N/A |
EPS (TTM) $-7.35 | Revenue (TTM) N/A | Return On Equity (TTM) -243.26% |
Profit Margin N/A | Debt to Equity 1.06 | Quarterly Earnings Growth YoY N/A |
About MetaVia Inc.
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
MetaVia Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $1.51 | $1.51 | +6.34% |
Jul 2026 | $1.43 | $1.42 | -0.35% |
Jun 2026 | $2.76 | $1.43 | -49.38% |
May 2026 | $1.46 | $2.81 | +93.47% |
Apr 2026 | $1.23 | $1.46 | +21.25% |
Mar 2026 | $1.53 | $1.20 | -20.53% |
Feb 2026 | $2.53 | $1.51 | -37.86% |
Jan 2026 | $8.55 | $2.43 | -71.45% |
Dec 2025 | $0.77 | $8.51 | +970.44% |
Nov 2025 | $1.07 | $0.80 | -18.88% |
Oct 2025 | $0.99 | $0.98 | +8.17% |
Sep 2025 | $0.67 | $0.91 | +39.81% |
MTVA Share Price FAQs
What is MetaVia Inc. share price today?
What is the 52 week high and 52 week low of MetaVia Inc. stock?
What is MTVA's market capitalisation today?
What is the 5 year returns of MTVA?
What is the high & low stock price of MTVA today?
Can I buy MTVA shares in India?